Free Trial
NASDAQ:PRLD

Prelude Therapeutics (PRLD) Stock Price, News & Analysis

Prelude Therapeutics logo
$0.68 -0.03 (-4.67%)
Closing price 04:00 PM Eastern
Extended Trading
$0.69 +0.01 (+1.78%)
As of 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Prelude Therapeutics Stock (NASDAQ:PRLD)

Key Stats

Today's Range
$0.66
$0.71
50-Day Range
$0.64
$1.22
52-Week Range
$0.63
$6.80
Volume
186,390 shs
Average Volume
259,535 shs
Market Capitalization
$37.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Hold

Company Overview

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Remove Ads

Prelude Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

PRLD MarketRank™: 

Prelude Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 464th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Prelude Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Prelude Therapeutics has received no research coverage in the past 90 days.

  • Read more about Prelude Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Prelude Therapeutics are expected to remain at ($1.81) per share in the coming year.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Prelude Therapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Prelude Therapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Prelude Therapeutics has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Prelude Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.35% of the float of Prelude Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Prelude Therapeutics has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Prelude Therapeutics has recently increased by 4.17%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Prelude Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Prelude Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.35% of the float of Prelude Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Prelude Therapeutics has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Prelude Therapeutics has recently increased by 4.17%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Prelude Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Prelude Therapeutics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Prelude Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $568,475.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    62.80% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    79.72% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Prelude Therapeutics' insider trading history.
Receive PRLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRLD Stock News Headlines

Three new patents reveal Elon and Trump’s secret “Project America”
Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR! He says these 5 stocks are trading for less than $2 right now… But they could soon SOAR in Trump’s first 100 days.
Prelude Therapeutics Founder Acquires 28% More Stock
Prelude Therapeutics CEO buys $467K in common stock
See More Headlines

PRLD Stock Analysis - Frequently Asked Questions

Prelude Therapeutics' stock was trading at $1.2750 at the beginning of 2025. Since then, PRLD stock has decreased by 47.1% and is now trading at $0.6750.
View the best growth stocks for 2025 here
.

Prelude Therapeutics Incorporated (NASDAQ:PRLD) announced its quarterly earnings results on Monday, March, 10th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.11. The firm had revenue of $4 million for the quarter.

Prelude Therapeutics (PRLD) raised $149 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities acted as the underwriters for the IPO.

Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Prelude Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
3/10/2025
Today
4/04/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PRLD
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$5.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+493.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-121,830,000.00
Pretax Margin
-4,383.90%

Debt

Sales & Book Value

Annual Sales
$7 million
Price / Cash Flow
N/A
Book Value
$4.32 per share
Price / Book
0.16

Miscellaneous

Free Float
20,473,000
Market Cap
$37.17 million
Optionable
Optionable
Beta
1.35
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

This page (NASDAQ:PRLD) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners